

Back to the Roots: Stentfreie Behandlung von Koronararterien

Donnerstag, 29. November 2018



Referent: Prof. Raban Jeger

Summary

- DES are the default strategy in the treatment of coronary artery disease but have limitations in small vessels with high rates of clinical endpoints
- DCB are a novel treatment strategy established for in-stent-restenoses
- In the presence of effective dual antiplatelet therapy and in the absence of high-grade dissections after balloon inflation, plain old balloon angioplasty can be performed safely
- Drugs such as paclitaxel assure good long-term results with positive remodeling
- In small native vessel disease, DCB have been proven non-inferior to DES regarding clinical endpoints
- Guidelines for the performance of DCB interventions have to be followed strictly to ensure good clinical results